Clearmind Medicine (CMND) announced a patent publication by the Instituto Mexicano de la Propriedad Industrial, the National Mexico Patent Office. The patent refers to the Company’s combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent is part of Clearmind’s collaboration with SciSparc (SPRC). Together, the two companies are researching combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: atai Life Sciences reports BPL-003 study results
- Rising High: Exclusive talk with pharmaceutical development company MIRA
- Clearmind Medicine announces shareholders meeting results
- Clearmind Medicine announces publication of European patent application
- SciSparc announces publication of European patent application